They found higher YKL-40 levels in MCI and AD patients compared to controls, and they also reported that YKL-40 levels predicted progression from MCI to AD, suggesting that this protein could have an increased relevance in discriminating cognitively normal individuals from MCI and AD patients, and that YKL-40 levels may be associated with disease progression. This evidence concerns the gene CHI3L1 and Alzheimer disease.